A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

NCT00985959 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: JNJ-26866138 0.7 mg/m2
DRUG: JNJ-26866138 1.0 mg/m2
DRUG: JNJ-26866138 1.3 mg/m2
DRUG: Melphalan
DRUG: Prednisolone

Sponsor

Janssen Pharmaceutical K.K.